Optimized Acute Treatment of Migraine Is Associated With Greater Productivity in People With Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
| Autor: | Buse DC; From the Albert Einstein College of Medicine, Bronx, New York (D.C.B., C.E.A., R.B.L.); Thomas Jefferson University, Philadelphia, Pennsylvania (S.J.N.); Medcurio, Oakland, California (W.(B.)F.S.); Vedanta Research, Chapel Hill, North Carolina (M.L.R.); MIST Research, Wilmington, North Carolina (K.M.F.); AbbVie, Irvine, California (A.M.A.)., Nahas SJ, Stewart WBF, Armand CE, Reed ML, Fanning KM, Manack Adams A, Lipton RB |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of occupational and environmental medicine [J Occup Environ Med] 2023 Apr 01; Vol. 65 (4), pp. e261-e268. Date of Electronic Publication: 2023 Jan 25. |
| DOI: | 10.1097/JOM.0000000000002801 |
| Abstrakt: | Objective: This study aimed to ascertain whether level of optimization of acute treatment of migraine is related to work productivity across the spectrum of migraine. Methods: Data were from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study, an internet-based longitudinal survey. Respondents with migraine who reported full-time employment and use of ≥1 acute prescription medication for migraine were included. We determined relationships among lost productive time (LPT; measured with the Migraine Disability Assessment Scale), acute treatment optimization (Migraine Treatment Optimization Questionnaire- ), and monthly headache days (MHDs). Results: There was a direct relationship between LPT and MHD category. Greater acute treatment optimization was associated with lower total LPT, less absenteeism, and less presenteeism within each MHD category. Conclusions: Optimizing acute treatment for migraine may reduce LPT in people with migraine and reduce indirect costs. Competing Interests: Conflict of interest: D.C.B. has received research support from the US Food and Drug Administration and the National Headache Foundation. She serves as consultant or advisory board member, or has received honoraria or research support from AbbVie/Allergan, Amgen, Biohaven, Colleguium, Eli Lilly and Company, Lundbeck, and Teva and for work on the editorial board of Current Pain and Headache Reports in the past year. S.J.N. has received honoraria for consulting from Alder/Lundbeck, Allergan/AbbVie, Amgen/Novartis (ended April 2021), Axsome (ended January 2022), BioDelivery Sciences (ended February 2022), Biohaven (ended November 2021), Eli Lilly, Fenix Group International (ended July 2021), Teva (ended October 2021), and Theranica (ended September 2022). She has received honoraria for speaking from Allergan/AbbVie (ended July 2021), Amgen/Novartis (ended June 2021), Eli Lilly (ended September 2021), and Teva (ended June 2021); research support from Teva (Ended March 2021); and honoraria for work in education or publishing from American Academy of Neurology, American Headache Society, Evolve Med Ed, Massachusetts Medical Society, MedLink Neurology, MJH Life Sciences, NACCME, Neurology Learning Network, Pennsylvania Neurologic Society, Springer, WebMD/Medscape, and Wolters-Kluwer. Furthermore, she has received legal fees for serving as a medical expert to Jackson & Campbell. (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American College of Occupational and Environmental Medicine.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|